Thymidin-5'-monophosphat | 3590-47-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷酸
• 英文名称: Thymidin-5'-monophosphat
• 英文别名: Thymidin-5'-phosphat；thymidine 5'-monophosphate；((2R,3S,4R,5R)-3,4-dihydroxy-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl phosphate；Thymidinmonophosphat；Thymidine monophosphate；5-Methyluridine 5'-monophosphate；[(2R,3S,4R,5R)-3,4-dihydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate
• CAS: 3590-47-4
• 化学式: C₁₀H₁₅N₂O₉P
• 分子量: 338.211
• InChiKey: IGWHDMPTQKSDTL-JXOAFFINSA-N

物化性质

• 密度：
  1.763±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  166
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  Thymidin-5'-monophosphat 在 亚磷酸三苯酯 、 2,2'-二硫二吡啶 、 H₉₆F-Fhit 、 magnesium chloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 P¹-5'-O-thymidine,P³-5'-O-uridine triphosphate
  参考文献：
  名称：

  将人类 Fhit（一种二腺苷三磷酸水解酶）改造为高效的二核苷多磷酸合酶

  摘要：

  假定的人类肿瘤抑制基因 FHIT 编码 Fhit，即脆弱的组氨酸三联体蛋白。Fhit 被认为参与涉及双核苷多磷酸的信号转导途径。Fhit 催化 P1-5'-O-腺苷-P3-5'-O-三磷酸腺苷 (Ap3A) 依赖 Mg2+ 水解为 AMP 和 MgADP。His96 突变为甘氨酸会使 Fhit 作为磷酸酐（如 Ap3A）水解的催化剂失效。然而，突变酶 H96G-Fhit 在核苷 5'-磷咪唑化物与核苷二磷酸和三磷酸的反应中有效催化磷酸酐键的合成。H96G-Fhit 可用于合成多种二核苷三磷酸和四磷酸。我们在此描述了使用 H96G-Fhit 催化 Ap3A、Ap3C、Ap3G、Ap3T、Ap3U、Cp3U、Tp3U、dAp3U、Ap4A、

  DOI：

  10.1021/ja0400640
• 作为产物：
  描述：

  5-甲基尿甙 在 1,8-双二甲氨基萘 、 三氯氧磷 、 水 作用下， 反应 0.4h， 以64%的产率得到Thymidin-5'-monophosphat
  参考文献：
  名称：

  Fully Automated Continuous Meso-flow Synthesis of 5′-Nucleotides and Deoxynucleotides

  摘要：

  The first continuous meso-flow synthesis of natural and non-natural 5'-nucleotides and deoxynucleotides is described, representing a significant advance over the corresponding in-flask method. By means of this meso-flow technique, a synthesis with time consumption and high-energy consumption becomes facile to generate products with great efficiency. An abbreviated duration, satisfactory output, and mild reaction conditions are expected to be realized under the present procedure.

  DOI：

  10.1021/op5002066

文献信息

• ADJUVANT IN THE FORM OF A LIPID-MODIFIED NUCLEIC ACID
  申请人：Hoerr Ingmar

  公开号：US20070280929A1

  公开（公告）日：2007-12-06

  The present invention relates to an immune-stimulating adjuvant in the form of a lipid-modified nucleic acid, optionally in combination with further adjuvants. The invention relates further to a pharmaceutical composition and to a vaccine, each containing an immune-stimulating adjuvant according to the invention, at least one active ingredient and optionally a pharmaceutically acceptable carrier and/or further auxiliary substances and additives and/or further adjuvants. The present invention relates likewise to the use of the pharmaceutical composition according to the invention and of the vaccine according to the invention for the treatment of infectious diseases or cancer diseases. Likewise, the present invention includes the use of the immune-stimulating adjuvant according to the invention in the preparation of a pharmaceutical composition for the treatment of cancer diseases or infectious diseases.

  本发明涉及一种免疫刺激佐剂，其形式为脂质修饰的核酸，可选地与其他佐剂结合。该发明还涉及一种含有根据本发明的免疫刺激佐剂、至少一种活性成分以及可选的药用载体和/或其他辅助物质和添加剂和/或其他佐剂的药物组合物和疫苗。本发明还涉及根据本发明的药物组合物和疫苗用于治疗传染病或癌症的用途。同样，本发明包括根据本发明的免疫刺激佐剂用于制备用于治疗癌症或传染病的药物组合物的用途。
• OLIGONUCLEOTIDE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20150376611A1

  公开（公告）日：2015-12-31

  The present invention provides an oligonucleotide having improved affinity for AGO2, and the like. The oligonucleotide has a nucleotide residue or a nucleoside residue represented by formula (I) wherein X 1 is an oxygen atom or the like, R 1 is formula (IIA) (wherein R 5A is halogen or the like, and R 6A is a hydrogen atom or the like) or formula (IVA) (wherein Y 3A is a nitrogen atom or the like, and Y 4A is CH or the like), or the like, R 2 is a hydrogen atom, hydroxy, halogen, or optionally substituted lower alkoxy, and R 3 is a hydrogen atom or the like} at the 5′ end thereof, and the nucleotide residue or the nucleoside residue binds to an adjacent nucleotide residue through the oxygen atom at position 3.

  本发明提供了一种具有改善对AGO2亲和力的寡核苷酸等。该寡核苷酸在其5'端具有由式(I)表示的核苷酸残基或核苷酸残基其中X 1 是氧原子或类似物，R 1 是式(IIA)（其中R 5A 是卤素或类似物，而R 6A 是氢原子或类似物）或式(IVA)（其中Y 3A 是氮原子或类似物，而Y 4A 是CH或类似物），或类似物，R 2 是氢原子、羟基、卤素或可选择地取代的较低烷氧基，而R 3 是氢原子或类似物}，并且该核苷酸残基或核苷酸残基通过位于位置3的氧原子与相邻核苷酸残基结合。
• OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20170354673A1

  公开（公告）日：2017-12-14

  An oligonucleotide having a nucleotide residue or a nucleoside residue represented by formula (I) wherein X 1 is an oxygen atom or the like, R 1 is formula (IIA) (wherein R 5A is halogen or the like, and R 6A is a hydrogen atom or the like), formula (IVA) (wherein Y 3A is a nitrogen atom or the like, and Y 4A is CH or the like), or the like, R 2 is a hydrogen atom, hydroxy, halogen, or optionally substituted lower alkoxy, and R 3 is a hydrogen atom or the like, or formula (VI) (wherein n2 is 1, 2 or 3)} at the 5′ end thereof, wherein the nucleotide residue or the nucleoside residue binds to an adjacent nucleotide residue through the oxygen atom at position 3, is provided.

  具有由式(I)表示的核苷酸残基或核苷酸残基的寡核苷酸其中X1是氧原子或类似物，R1是式(IIA)（其中R5A是卤素或类似物，而R6A是氢原子或类似物），式(IVA)（其中Y3A是氮原子或类似物，而Y4A是CH或类似物），或类似物，R2是氢原子，羟基，卤素，或可选择地取代的较低烷氧基，而R3是氢原子或类似物，或式(VI)（其中n2为1、2或3）}在其5'端，其中核苷酸残基或核苷酸残基通过位于位置3的氧原子与相邻核苷酸残基结合。
• Dibenzotetraaza[14]annulene–adenine conjugate recognizes complementary poly dT among ss-DNA/ss-RNA sequences
  作者：Marijana Radić Stojković、Marko Škugor、Sanja Tomić、Marina Grabar、Vilko Smrečki、Łukasz Dudek、Jarosław Grolik、Julita Eilmes、Ivo Piantanida

  DOI：10.1039/c3ob40519b

  日期：——

  Among three novel DBTAA derivatives only the DBTAA–propyl–adenine conjugate 1 showed recognition of the consecutive oligo dT sequence by increased affinity and specific induced chirooptical response in comparison to other single stranded RNA and DNA; whereby of particular importance is the up until now unique efficient differentiation between dT and rU. At variance, its close analogue DBTAA–hexyl–adenine 2 did not reveal any selectivity between ss-DNA/RNA pointing out the important role of steric factors (linker length); moreover non-selectivity of the reference compound (3, lacking adenine) stressed the importance of adenine interactions in the 1 selectivity.

  在三种新型DBTAA衍生物中，只有DBTAA-丙基-腺苷 conjugate 1 显示出对连续的寡聚胸苷序列的识别，表现出比其他单链RNA和DNA更高的亲和力和特定的诱导手性光学响应；其中，尤其重要的是迄今为止独特的对dT和rU的高效区分。相对而言，其近似物DBTAA-己基-腺苷 2 并未表现出ss-DNA/RNA之间的选择性，突显了空间因素（连接子长度）的重要作用；此外，参考化合物（3，缺乏腺苷）的非选择性强调了腺苷相互作用在2的选择性中的重要性。
• Accelerating chemical replication steps of RNA involving activated ribonucleotides and downstream-binding elements
  作者：Stephanie R. Vogel、Christopher Deck、Clemens Richert

  DOI：10.1039/b510775j

  日期：——

  Template-directed single nucleotide extension of an RNA primer with oxyazabenzotriazolides of ribonucleotides is shown to be fast and sequence-selective; downstream-binding RNA strands contribute to the acceleration of the reaction.

  研究表明，用核糖核苷酸的氧氮苯并三唑类对 RNA 引物进行模板定向单核苷酸延伸是快速且具有序列选择性的；下游结合的 RNA 链有助于加速反应。